A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 15 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 25 Apr 2018 Status changed from not yet recruiting to recruiting.